Navigation Links
Derma Sciences Reports First Quarter 2008 Results

Sales Reach $11.7 Million

PRINCETON, N.J., May 15 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound-care products, announced results today for the first quarter ended March 31, 2008. For the quarter, sales were up 47 percent from the previous year, including sales from the newly acquired First Aid Division. The Company reported a loss consistent with earlier guidance, due primarily to higher than expected integration costs associated with its First Aid Division.

For the quarter, the Company reported sales of $11.7 million, compared to sales in the first quarter of the previous year of $8.0 million. Gross margins declined to 27 percent from the previous year's 35 percent, due to the additional integration costs causing temporary downward margin pressure on the First Aid Division's products and a shortfall in expected overhead absorption in the company's manufacturing facility in Toronto. This shortfall was primarily due to timing related issues on two large private label orders. SG&A costs were up significantly, consistent with the Company's growth strategy that was implemented in the second half of 2007. The Company reported a loss of $1.4 million or $0.04 loss per share, vs. a loss of $138,953 or $0.01 loss per share in the first quarter of 2007.

CEO Ed Quilty commented, "We are seeing gratifying growth in our sales from our proprietary branded business for products such as our MEDIHONEY(TM). We continued to expand the sales force, as our strategic plan specifies, and at the end of the quarter we had 10 sales reps and one clinical nurse, versus a year-earlier sales force of 2 sales reps. MEDIHONEY sales were $319,179 for the quarter -- on target for the product's projected first full quarter of sales. There have been over 800 clinical evaluations within the US and Canada since the product was launched last fall. Also, we have two additional 510K clearances for line extensions that we will bring to market in Q2, and we are confident that we will have MEDIHONEY into the OTC market by the end of the year.

"Although we have had some manufacturing cost issues in our new First Aid division, we are successfully navigating through those and are nearing our long-term cost structure goals. We are confident once our integration is complete that we will be able to layer consistent strong sales growth onto this division."

Quilty continued, "We are gearing up to launch our novel MOBILITY1(TM) intermittent pneumatic compression device later this year, and are in various phases of negotiation with several other companies for the licensing/distribution of novel wound care products we intend to launch over the next eighteen months. These new products will help to leverage our growing sales force, and will allow us to return to profitability more quickly.

"Lastly, we continue to make progress with our products under development. The Phase II protocol for DSC127, our novel angiotensin analog for wound healing and scar prevention, is almost complete and will be submitted to the FDA shortly thereafter. With regard to our novel GUARDION(TM) line of barrier dressings, the most recent communications with the FDA give us confidence that we are close to marketing clearance. We look forward to having this best-in-class product, with effectiveness against superbugs such as MRSA, in the market by the end of the year."

CFO John Yetter pointed out that on April 2, the Company completed a private placement of $6.1 million with a group of institutional investors, and that the funds from this placement give the Company the financial resources to execute its growth plans.

Quilty said that the Company believes that both its principal product segments will continue to grow quickly, and referenced recent announcements of contracts with MedAssets and Amerinet, large group purchasing organizations. He pointed out that while the Company's proprietary branded products are more visible to the public -- MEDIHONEY being the most prominent example at present -- the Company's private-label and OEM business is expanding at a rapid rate.

He continued, "Sales in our First Aid Division were strong during the quarter, and as the integration of that operation progresses in the quarters ahead, we expect to see improving margins. We have excellent new business opportunities in the First Aid Division for contracts that would begin in late 2008 and into 2009, and expect to see solid growth in that business. The volume-oriented manufacturing for our private-label segment has enabled us to outfit our state-of-the-art manufacturing facilities."

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO

(609) 514-4744 Brian Kennedy (media)

(212) 691-8087



Consolidated Statements of Operations


Three Months ended March 31,

2008 2007

Net Sales $11,724,822 $7,965,797

Cost of sales 8,516,164 5,161,369

Gross Profit 3,208,658 2,804,428

Operating expenses

Selling, general and administrative 4,386,866 2,668,154

Research and development 48,108 125,000

Total operating expenses 4,434,974 2,793,154

Operating (loss) income (1,226,316) 11,274

Other expense, net:

Interest expense 264,915 50,246

Other expense, net 8,614 26,557

Total other expense, net 273,529 76,803

Loss before (benefit) provision for income taxes (1,499,845) (65,529)

(Benefit) provision for income taxes (90,057) 73,424

Net Loss $(1,409,788) $(138,953)

Loss per common share - basic and diluted $(0.04) $(0.01)

Shares used in computing loss per common share -

basic and diluted 34,038,207 25,246,596

SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
6. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
9. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
10. Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications
11. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
Post Your Comments:
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... how current market conditions have influenced the most recent ... Regulus Therapeutics Inc. (NASDAQ: RGLS ), Abeona ... Inc. (NASDAQ: TBPH ), and Sage Therapeutics ... new research report by Grand View Research, global Biotech market size ...
(Date:1/19/2017)... India , Jan. 19, 2017  Market Research Future has ... Global Market for Liquid Biopsy is growing rapidly and expected to ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a ... growth figures and boom in the coming future. There has been ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, is proud ... 21 CFR Part 11-compliant email client designed to provide product vigilance departments with ...
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... ... for tech innovators, engineers, and scientists from around the world, was today awarded ... The awards program is based entirely on merit and decided upon by a ...
Breaking Biology Technology:
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
Breaking Biology News(10 mins):